Amgen, Inc. (NASDAQ:AMGN) Shares Purchased by Vivaldi Capital Management LLC

Share on StockTwits

Vivaldi Capital Management LLC lifted its position in shares of Amgen, Inc. (NASDAQ:AMGN) by 12.7% during the second quarter, Holdings Channel.com reports. The firm owned 1,786 shares of the medical research company’s stock after acquiring an additional 201 shares during the period. Vivaldi Capital Management LLC’s holdings in Amgen were worth $329,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds and other institutional investors have also recently modified their holdings of the company. Advisors Preferred LLC acquired a new stake in Amgen during the second quarter valued at $30,000. Arbor Wealth Management LLC grew its position in Amgen by 154.5% during the second quarter. Arbor Wealth Management LLC now owns 168 shares of the medical research company’s stock valued at $31,000 after buying an additional 102 shares during the period. C J Advisory Inc acquired a new stake in Amgen during the first quarter valued at $40,000. Ashburton Jersey Ltd acquired a new stake in Amgen during the second quarter valued at $42,000. Finally, Sound Income Strategies LLC grew its position in shares of Amgen by 402.1% during the 2nd quarter. Sound Income Strategies LLC now owns 236 shares of the medical research company’s stock valued at $43,000 after acquiring an additional 189 shares during the period. 76.24% of the stock is currently owned by institutional investors and hedge funds.

A number of equities research analysts have recently commented on the company. BidaskClub cut Amgen from a “hold” rating to a “sell” rating in a research report on Thursday, September 12th. Citigroup reissued a “buy” rating on shares of Amgen in a report on Monday, August 12th. Oppenheimer set a $240.00 price objective on Amgen and gave the company a “buy” rating in a report on Monday, September 9th. Credit Suisse Group reissued an “outperform” rating and issued a $225.00 price objective (up from $202.00) on shares of Amgen in a report on Friday, August 16th. Finally, Wells Fargo & Co reissued a “market perform” rating and issued a $220.00 price objective (up from $202.00) on shares of Amgen in a report on Tuesday, August 27th. They noted that the move was a valuation call. One research analyst has rated the stock with a sell rating, ten have assigned a hold rating and ten have issued a buy rating to the company’s stock. The stock has an average rating of “Hold” and a consensus target price of $217.33.

In other Amgen news, Director R Sanders Williams sold 425 shares of Amgen stock in a transaction on Wednesday, August 7th. The shares were sold at an average price of $183.04, for a total transaction of $77,792.00. Following the sale, the director now owns 16,336 shares of the company’s stock, valued at approximately $2,990,141.44. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, Director Ronald D. Sugar sold 2,000 shares of Amgen stock in a transaction on Wednesday, July 3rd. The stock was sold at an average price of $187.58, for a total transaction of $375,160.00. Following the sale, the director now directly owns 16,336 shares in the company, valued at approximately $3,064,306.88. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 17,851 shares of company stock worth $3,659,900. 0.25% of the stock is currently owned by corporate insiders.

AMGN stock traded up $1.29 during trading on Friday, hitting $196.94. The stock had a trading volume of 3,068,333 shares, compared to its average volume of 2,772,191. The company has a debt-to-equity ratio of 2.58, a current ratio of 2.89 and a quick ratio of 2.60. Amgen, Inc. has a twelve month low of $166.30 and a twelve month high of $211.90. The stock has a market capitalization of $116.97 billion, a P/E ratio of 13.68, a PEG ratio of 2.54 and a beta of 1.11. The company’s 50-day moving average price is $199.24 and its two-hundred day moving average price is $185.38.

Amgen (NASDAQ:AMGN) last issued its quarterly earnings results on Tuesday, July 30th. The medical research company reported $3.97 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $3.58 by $0.39. The firm had revenue of $5.87 billion for the quarter, compared to analyst estimates of $5.67 billion. Amgen had a return on equity of 76.17% and a net margin of 33.78%. The business’s revenue was down 3.1% on a year-over-year basis. During the same period in the previous year, the company posted $3.83 earnings per share. As a group, sell-side analysts expect that Amgen, Inc. will post 14.3 EPS for the current fiscal year.

The firm also recently announced a quarterly dividend, which was paid on Friday, September 6th. Shareholders of record on Thursday, August 15th were paid a dividend of $1.45 per share. The ex-dividend date of this dividend was Wednesday, August 14th. This represents a $5.80 annualized dividend and a yield of 2.95%. Amgen’s dividend payout ratio (DPR) is presently 40.28%.

About Amgen

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. It offers products for the treatment of oncology/hematology, cardiovascular, inflammation, bone health, and neuroscience. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta, a pegylated protein to treat cancer patients; Prolia to treat postmenopausal women with osteoporosis; Aranesp to treat anemia; Xgeva for skeletal-related events prevention; Sensipar/Mimpara products to treat sHPT in chronic kidney disease; and EPOGEN to treat a lower-than-normal number of red blood cells.

Recommended Story: S&P 500 Index

Want to see what other hedge funds are holding AMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen, Inc. (NASDAQ:AMGN).

Institutional Ownership by Quarter for Amgen (NASDAQ:AMGN)

Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with MarketBeat.com's FREE daily email newsletter.